Answer
Ketoconazole, a strong CYP3A4 inhibitor, increases Inrebic exposure, potentially increasing adverse reactions; if it cannot be replaced, the Inrebic dose should be reduced and safety carefully monitored at least weekly.
Sources for this answer
- Inrebic 100 mg hard capsulesBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 9Document updated
Sources checked